Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BIIB vs AMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BIIB Captures Overall Composite Edge (50.2 HOLD vs 48.9 HOLD), While AMD Leads 4–2 on Growth & Valuation Pillars
BIIB Overall Winner
6-Pillar Tally: BIIB 2 – 4 AMD
Matrix Metrics: BIIB 6 – 4 AMD
As of Nov 16, 2026, Biogen Inc. (BIIB) captures the overall head-to-head institutional edge over Advanced Micro Devices (AMD) on higher Unified Composite conviction (50.2/100 HOLD vs. 48.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while AMD wins 4–2 across the 6-pillar growth and valuation breakdown. BIIB trades at $252.72 (15.6x Forward P/E, 23.5% operating margin) versus AMD at $508.41 (30.2x Forward P/E, 17.8% operating margin).
- Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. AMD 48.9/100 HOLD) and 0.27β · 36% Vol risk profile, whereas AMD leads top-line expansion (+44.7% YoY revenue growth, 0.50x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BIIB vs AMD
BIIB
Head-to-Head Winner
Biogen Inc. Common Stock
$252.72
-0.27% 1D
Market Cap
$37.0B
TTM Revenue
$10.3B
Forward P/E
15.6x
Beta / 30D Vol
0.27β · 36% Vol
Unified Composite Score
50.2
HOLD
Tech 45.0
Fund 52.0
Flow 64.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
AMD
Advanced Micro Devices
$508.41
-4.8% 1D
Market Cap
$959.9B
TTM Revenue
$45.4B
Forward P/E
30.2x
Beta / 30D Vol
3.60β · 118% Vol
Unified Composite Score
48.9
HOLD
Tech 23.0
Fund 42.0
Flow 68.0
Mom 37.6
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (BIIB 2 – 4 AMD)
1. Valuation Multiples
BIIB
Forward P/E
15.6x
30.2x
Trailing P/E
109.9x
125.1x
PEG Ratio
3.45x
0.50x
EV / Revenue
4.2x
21.2x
2. Growth & Scale
AMD
Revenue Growth (YoY)
+10.6%
+44.7%
Earnings Growth (YoY)
-84.8%
+93.8%
TTM Revenue (USD)
$10.3B
$45.4B
Market Cap
$37.0B
$959.9B
3. Profitability & Quality
BIIB
Gross Margin
75.8%
56.0%
Operating Margin
23.5%
17.8%
Net Profit Margin
3.4%
16.8%
Return on Equity (ROE)
1.9%
12.0%
4. Balance Sheet & Cash Flow
AMD
Cash Generation (TTM)
$1.64B
$7.06B
Cash Flow Margin
16.0%
15.5%
Net Cash / Leverage
$6.50B Net Debt (0.41x D/E)
$1.51B Net Debt (0.13x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AMD
Options Structure Phase
CONSOLIDATION
CONSOLIDATION
Current IV / %ile
18.4% (6th %ile)
78.1% (10th %ile)
Put/Call OI Skew
0.77x (Call-Skewed)
1.07x (Balanced)
OBV Trend / Tech Phase
ACCUMULATION · Markup
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
AMD
OpEx & R&D Intensity
52.3% of Rev ($5.39B)
38.2% of Rev ($17.4B)
90D R&D Disclosures
0 papers
7 papers
Competitive Moat
Scale & Operating Efficiency Moat
Concentrated Oligopoly Moat
Supply-Chain Role
Drug Manufacturers - General Operator
AI Accelerator & Server Chiplet Designer
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BIIB (6) vs AMD (4)| Institutional Metric | BIIB | AMD | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $37.0B | $959.9B | AMD | |
| Trailing P/E Ratio | 109.9x | 125.1x | BIIB | |
| Forward P/E Ratio | 15.6x | 30.2x | BIIB | |
| Revenue Growth (YoY) | +10.6% | +44.7% | AMD | |
| Operating Margin (TTM) | 23.5% | 17.8% | BIIB | |
| Net Profit Margin | 3.4% | 16.8% | AMD | |
| Return on Equity (ROE) | 1.9% | 12.0% | AMD | |
| 52-Week Range Position | 92% ($160–$261) | 68% ($188–$659) | BIIB | |
| Beta / 30D Volatility | 0.27β · 36% Vol | 3.60β · 118% Vol | BIIB | |
| Unified Institutional Score | 50.2 / 100 (HOLD) | 48.9 / 100 (HOLD) | BIIB | |
| Trailing 12M Revenue (USD) | $10.3B | $45.4B | Scale | |
| Gross Profit Margin (TTM) | 75.8% | 56.0% | Quality | |
| PEG Ratio & EV / Revenue | 3.45x PEG · 4.2x EV/Rev | 0.50x PEG · 21.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.64B ($6.50B Net Debt (0.41x D/E)) | $7.06B ($1.51B Net Debt (0.13x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BIIB +12.48 pp
3M Horizon
BIIB +13.94 pp
6M Horizon
BIIB +10.92 pp
1Y Horizon
AMD +51.63 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BIIB Revenue | AMD Revenue | BIIB Op. Margin | AMD Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $13.4B | $6.47B | 43.8% | 7.0% | BIIB |
| FY2019 | $14.4B | $6.73B | 49.0% | 9.4% | BIIB |
| FY2020 | $13.4B | $9.76B | 33.8% | 14.0% | BIIB |
| FY2021 | $11.0B | $16.4B | 25.9% | 22.2% | BIIB |
| FY2022 | $10.2B | $23.6B | 29.9% | 5.4% | BIIB |
| FY2023 | $9.84B | $22.7B | 11.8% | 1.8% | BIIB |
| FY2024 | $9.68B | $25.8B | 16.9% | 7.4% | BIIB |
| FY2025 | $9.89B | $34.6B | 13.1% | 10.7% | BIIB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BIIB
CONSOLIDATION
Current IV
18.4%
IV Percentile
6th %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AMD
CONSOLIDATION
Current IV
78.1%
IV Percentile
10th %ile
Put/Call OI Skew
1.07x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
$500.00
Call Wall Magnet
$600.00
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Put Floor: $500.00 (-1.7%)
Spot: $508.41
Call Magnet: $600.00 (+18.0%)
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BIIB Moat Profile
Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
OpEx & R&D Reinvestment
52.3% of Rev ($5.39B)
90D Engineering Disclosures
0 Published
AMD Moat Profile
Concentrated Oligopoly Moat
AI Accelerator & Server Chiplet Designer
OpEx & R&D Reinvestment
38.2% of Rev ($17.4B)
90D Engineering Disclosures
7 Published · LLM Efficiency / Architecture
Taiwan Semiconductor Manufacturing Company
GlobalFoundries
Samsung Electronics
ASE Technology Holding
Edge AI / Inference Chips
Hardware-Agnostic ML Compilers
Inference Serving / Speculative Decoding
KV-Cache / Attention Memory Compression
Mixture-of-Experts / Sparse Models
Investor FAQ BIIB vs AMD Key Questions & Quantitative Answers
As of Nov 16, 2026, Biogen Inc. (BIIB) captures the overall head-to-head institutional edge over Advanced Micro Devices (AMD) on higher Unified Composite conviction (50.2/100 HOLD vs. 48.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while AMD wins 4–2 across the 6-pillar growth and valuation breakdown. BIIB trades at $252.72 (15.6x Forward P/E, 23.5% operating margin) versus AMD at $508.41 (30.2x Forward P/E, 17.8% operating margin). Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. AMD 48.9/100 HOLD) and 0.27β · 36% Vol risk profile, whereas AMD leads top-line expansion (+44.7% YoY revenue growth, 0.50x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
AMD leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with AMD at +44.7% YoY revenue growth and +93.8% YoY earnings growth on $45.4B TTM revenue (56.0% gross margin, 17.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BIIB cumulative revenue shifted -26.5% while AMD shifted +435.4%. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus 38.2% of Rev ($17.4B) (7 disclosures) for AMD.
BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas AMD trades at 30.2x Forward P/E, 125.1x Trailing P/E, 0.50x PEG, and 21.2x EV/Revenue (15.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus AMD (12.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, AMD carries 78.1% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.60β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AMD vs BIIB · Reverse Pair
BIIB vs REGN
· Sector Peer
BIIB vs AMGN
· Sector Peer
BIIB vs GILD
· Sector Peer
AMD vs INTC
· Sector Peer
AMD vs MU
· Sector Peer
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma